https://adisinsight.springer.com/drugs/800087179?error=cookies_not_supported&code=bff0648c-a307-470a-abe3-12171893e7b3
Pertuzumab/trastuzumab biosimilar - Shanghai Henlius Biotech - AdisInsight
A biosmilar of the fixed dose combination of Pertuzumab and Trastuzumab [See Adisinsight 800051349] designated as 'HLX319' is being developed by Shanghai
shanghai henliuspertuzumabtrastuzumabbiosimilarbiotech
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-unit-ties-up-with-shanghai-henlius-biotech/articleshow/117981929.cms
Dr Reddy's unit ties up with Shanghai Henlius Biotech - The Economic Times
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Darzalex. Henlius will...